LXRX Lexicon Pharmaceuticals, Inc. - Common Stock

NASDAQ · Pharmaceuticals · SEC EDGAR에서 보기 ↗
$2.45
가격 · 8월 19, 2026
기준 재무 정보 8월 6, 2026
52주 범위
$1–$3
86% of range
애널리스트 평점
BUY
11 analysts
목표 주가
$4
+58% upside
P/E (TTM)
-17.5
ROE
-39.7%
순이익률
-101.1%

Lexicon Pharmaceuticals, Inc. - Common Stock 정보 위키백과 회사 개요

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

더 보기

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

Company history

Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.

The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.

In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.

Technology

Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.

The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.

In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.

Locations

Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.

Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.

== References ==

출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗

Wikidata ↗

LXRX 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위

가격
$2.44
시가총액
$894M
P/E (TTM)
-17.5
EPS (TTM)
$-0.14
매출 (TTM)
$50M
배당 수익률
—
ROE
-39.7%
부채/자본
0.5
52주 범위
$1 – $3

LXRX 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의

10년 성과 매출, 순이익, 마진 및 EPS 추세

매출 및 순이익 $50M
10-point trend, -37.2%
2016-12-31 → 2025-12-31
EPS $-0.14
9-point trend, +88.0%
2017-12-31 → 2025-12-31
잉여현금흐름 $-68M
10-point trend, +61.4%
2016-12-31 → 2025-12-31
마진 -101.1%

가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?

지표
5년 추세
LXRX
동종업계 중앙값
P/E (TTM)
5-point trend, -25.1%
-17.5
29.9
P/S (TTM)
5-point trend, +514.6%
18.0
14.4
P/B
5-point trend, +3.5%
8.3
4.4
EV / EBITDA
5-point trend, +1.2%
-17.6
—
Price / FCF (주가 / FCF)
5-point trend, -259.3%
-13.2
—

수익성 총, 영업 및 순이익률; ROE, ROA, ROIC

지표
5년 추세
LXRX
동종업계 중앙값
Operating Margin (영업이익률)
5-point trend, +99.7%
-98.2%
—
Net Profit Margin (순이익률)
5-point trend, +99.7%
-101.1%
0.70%
ROA
5-point trend, +59.6%
-20.8%
-0.55%
ROE
5-point trend, +38.9%
-39.7%
-2.5%

재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성

지표
5년 추세
LXRX
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
5-point trend, +574.1%
0.5
—
Current Ratio (유동비율)
5-point trend, +21.5%
4.9
3.9
Quick Ratio (당좌 비율)
5-point trend, +20.5%
4.7
—

성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR

지표
5년 추세
LXRX
동종업계 중앙값
Revenue YoY (매출 YoY)
5-point trend, +16612.4%
60.2%
—
Revenue CAGR 3Y (매출 CAGR 3년)
5-point trend, +16612.4%
610.2%
—
Revenue CAGR 5Y (매출 CAGR 5년)
5-point trend, +16612.4%
15.7%
—

주당 지표 EPS, 주당 순자산, 주당 현금 흐름, 주당 배당금

지표
5년 추세
LXRX
동종업계 중앙값
EPS (Diluted) (EPS (희석))
5-point trend, +76.7%
$-0.14
—

자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율

지표
5년 추세
LXRX
동종업계 중앙값

LXRX 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력

매수 11 명의 애널리스트
  • 적극 매수 3 27.3%
  • 매수 5 45.5%
  • 보유 3 27.3%
  • 매도 0 0.0%
  • 적극 매도 0 0.0%

12개월 목표 주가

5 명의 애널리스트 · 2026-08-19
중앙값 목표 $3.10 +26.8%
평균 목표 $3.86 +57.7%

실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일

평균 서프라이즈
0.03%
기간 EPS Actual EPS 예상 서프라이즈
2026년 6월 30일 $-0.07 $-0.05 -0.02%
2026년 3월 31일 $0.00 $-0.04 0.04%
2025년 12월 31일 $-0.04 $-0.07 0.03%
2025년 9월 30일 $-0.04 $-0.07 0.03%
2025년 6월 30일 $0.01 $-0.08 0.09%
2025년 3월 31일 $-0.07 $-0.10 0.03%

동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업

티커 시가총액 P/E 매출 YoY 순이익률 ROE 매출 총이익률
LXRX $421M -8.2 60.2% -101.1% -39.7% —
ANRO $568M -8.1 — — -46.1% —
EYPT $1.51B -5.8 -27.5% -739.4% -84.0% —
OMER $1.23B -343.6 — — 1.9% —
PCRX $1.06B 161.8 3.6% 0.97% 0.97% —
COLL $1.47B 26.8 23.6% 8.1% 23.5% 59.4%
AMPH $1.22B 13.2 -1.7% 13.6% 12.7% 49.5%
ACRS $363M -5.7 -58.2% -829.6% -55.3% —
SGP — — — — 50.0% —
LLY — 46.8 44.7% 31.7% 101.2% —

전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름

손익계산서 16
LXRX의 연간 손익계산서 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +117.9% $50M $31M $1M $139.0K $298.0K $24M $322M $63M $92M $79M $130M $23M
Cost of Revenue 11-point trend, +274000.00 $274.0K $616.0K $85.0K $0 $0 $2M $3M $2M $2M $0 $0 ·
R&D Expense 12-point trend, -31.5% $61M $84M $59M $53M $55M $154M $92M $100M $152M $164M $95M $89M
SG&A Expense 12-point trend, +92.3% $37M $143M $114M $48M $32M $47M $57M $64M $66M $43M $24M $19M
Operating Expenses 12-point trend, -19.9% $99M $228M $173M $101M $87M $204M $181M $166M $222M $206M $129M $123M
Operating Income 12-point trend, +51.3% $-49M $-197M $-172M $-101M $-87M $-48M $141M $-103M $-131M $-127M $1M $-100M
Interest Expense 9-point trend, +23.4% · · · $3M $802.0K $15M $21M $21M $7M $7M $7M $2M
Other Non-op 12-point trend, +206.4% $7M $12M $8M $2M $134.0K $3M $3M $4M $2M $2M $572.0K $2M
Pretax Income 8-point trend, +12.6% · · · · $-88M $-59M $124M $-121M $-136M $-131M $-5M $-100M
Income Tax 7-point trend, +100.0% · $0 $0 $0 $0 · · · · $0 $0 $-70.0K
Net Income 12-point trend, +49.8% $-50M $-200M $-177M $-102M $-88M $-59M $130M $-121M $-123M $-131M $-5M $-100M
EPS (Basic) 9-point trend, +88.0% $-0.14 $-0.63 $-0.80 $-0.62 $-0.60 $-0.53 $1.23 $-1.14 $-1.17 · · ·
EPS (Diluted) 9-point trend, +88.0% $-0.14 $-0.63 $-0.80 $-0.62 $-0.60 $-0.53 $1.16 $-1.14 $-1.17 · · ·
Shares (Basic) 5-point trend, +149.3% 363,053,000 320,031,000 221,130,000 165,733,000 145,652,000 · · · · · · ·
Shares (Diluted) 9-point trend, +245.0% 363,053,000 320,031,000 221,130,000 165,733,000 145,652,000 110,841,000 116,747,000 105,830,000 105,237,000 · · ·
EBITDA 11-point trend, +50.9% $-48M $-197M $-171M $-100M $-87M $-45M $145M $-100M $-133M $-135M · $-98M
대차대조표 30
LXRX의 연간 대차대조표 데이터
지표 추세 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, -75.0% $34M $67M $22M $46M $64M $126M $36M $80M $62M $47M $203M $137M
Short-term Investments 12-point trend, -69.4% $62M $171M $148M $92M $23M $26M $236M $80M $249M $300M $318M $202M
Receivables 12-point trend, +130.3% $2M $3M $1M $28.0K $14.0K $395.0K $57M $6M $5M $7M $911.0K $1M
Inventory 9-point trend, +281000.00 $281.0K $231.0K $381.0K $0 · $0 $4M $5M $2M $0 · ·
Other Current Assets 12-point trend, -37.0% $3M $5M $5M $2M $2M $5M $5M $3M $4M $4M $10M $5M
Current Assets 12-point trend, -72.4% $102M $246M $177M $141M $89M $158M $338M $173M $322M $358M $532M $369M
PP&E (Net) 12-point trend, +72.5% $2M $2M $2M $2M $1M $295.0K $14M $16M $18M $19M $21M $1M
PP&E (Gross) 12-point trend, -87.8% $5M $5M $7M $6M $6M $6M $76M $76M $76M $79M $81M $37M
Accum. Depreciation 12-point trend, -92.5% $3M $2M $5M $4M $5M $6M $62M $60M $59M $60M $59M $36M
Goodwill Flat — no change across 12 periods $45M $45M $45M $45M $45M $45M $45M $45M $45M $45M $45M $45M
Intangibles 6-point trend, -63.0% · · · · · · $20M $50M $52M $53M $53M $53M
Other Non-current Assets 12-point trend, -89.2% $368.0K $368.0K $828.0K $412.0K $2M $1M $2M $285.0K $429.0K $461.0K $433.0K $3M
Total Assets 12-point trend, -60.8% $185M $298M $229M $194M $137M $204M $418M $284M $437M $476M $652M $471M
Accounts Payable 12-point trend, -76.4% $3M $15M $14M $10M $9M $5M $12M $12M $39M $53M $20M $13M
Accrued Liabilities 12-point trend, +30.3% $13M $30M $17M $13M $13M $30M $42M $21M $12M $32M $25M $10M
Current Liabilities 12-point trend, -53.6% $21M $45M $32M $23M $22M $47M $65M $37M $105M $165M $123M $45M
Capital Leases 4-point trend, +21.7% $7M $5M $5M $5M · · · · · · · ·
Deferred Tax 6-point trend, -100.0% · · · · · · $0 $6M $6M $19M $19M $19M
Other Non-current Liabilities 12-point trend, -69.5% $7M $7M $5M $5M $1M $611.0K $1M $238.0K $292.0K $805.0K $14M $24M
Total Liabilities 12-point trend, -58.7% $77M $152M $136M $77M $23M $47M $301M $311M $368M $318M $366M $187M
Long-term Debt 11-point trend, -49.8% $54M $100M · $49M $0 $12M $249M $250M $252M $101M $106M $108M
Total Debt 10-point trend, -49.8% $54M $100M $100M · $0 $12M $245M $245M $246M $101M · $108M
Common Stock 12-point trend, +251.9% $366.0K $363.0K $245.0K $189.0K $150.0K $142.0K $106.0K $106.0K $106.0K $105.0K $104.0K $104.0K
Paid-in Capital 12-point trend, +53.2% $2.13B $2.12B $1.86B $1.71B $1.61B $1.56B $1.46B $1.45B $1.44B $1.41B $1.40B $1.39B
Retained Earnings 12-point trend, -82.7% $-2.02B $-1.97B $-1.77B $-1.59B $-1.49B $-1.40B $-1.34B $-1.47B $-1.37B $-1.25B $-1.11B $-1.10B
Treasury Stock 12-point trend, +117.0% $5M $5M $3M $2M $8M $5M $4M $3M $2M $3M $3M $2M
AOCI 12-point trend, +147.6% $30.0K $119.0K $31.0K $-428.0K $-10.0K $-6.0K $84.0K $-12.0K $-222.0K $-195.0K $-219.0K $-63.0K
Stockholders' Equity 12-point trend, -62.1% $108M $146M $93M $117M $114M $156M $117M $-26M $68M $168M $286M $284M
Liabilities + Equity 12-point trend, -60.8% $185M $298M $229M $194M $137M $204M $418M $284M $437M $476M $652M $471M
Shares Outstanding 11-point trend, +252.9% 365,848,216 363,020,303 · 189,214,000 150,082,000 142,289,000 106,679,000 106,162,000 105,711,000 104,582,000 103,860,000 103,663,000
현금 흐름 17
LXRX의 연간 현금 흐름 데이터
지표 추세 202520242023202220212020201920182017201620152014
D&A 12-point trend, -67.8% $621.0K $534.0K $554.0K $427.0K $292.0K $3M $4M $4M $3M $2M $727.0K $2M
Stock-based Comp 12-point trend, +76.8% $13M $13M $14M $12M $11M $13M $14M $12M $9M $7M $7M $7M
Deferred Tax 9-point trend, +100.0% · · · $0 $0 $0 $-6M $0 $-13M $0 $0 $-70.0K
Amort. of Intangibles 2-point trend, +20.0% · · · · · · · $2M $2M · · ·
Other Non-cash 11-point trend, -296.5% $-31M $8M $328.0K $1M $-10M $-101M $-28M $-43M $-57M $-44M · $16M
Operating Cash Flow 12-point trend, +10.3% $-68M $-179M $-162M $-89M $-87M $-143M $114M $-149M $-185M $-176M $185M $-76M
CapEx 12-point trend, -100.0% $0 $1M $470.0K $1M $1M $87.0K $70.0K $95.0K $228.0K $231.0K $910.0K $80.0K
Investing Cash Flow 12-point trend, +204.2% $113M $-15M $-50M $-71M $2M $381M $-156M $170M $51M $18M $-117M $-108M
Debt Issued 11-point trend, -100.0% $0 $0 $50M $49M · $0 $0 $13M $146M $0 $0 $84M
Net Debt Issued 10-point trend, -100.0% $0 $0 · $49M $-12M $-217M $-1M $-2M $144M $-2M · $82M
Stock Issued 12-point trend, -100.0% $0 $0 $139M $94M $37M $70M $0 $732.0K $8M $4M $114.0K $202M
Stock Repurchased 11-point trend, +95.0% · $2M $824.0K $864.0K $3M $1M $941.0K $972.0K $2M $621.0K $357.0K $887.0K
Net Stock Activity 11-point trend, -100.0% $0 $-2M $138M $93M $34M $69M $-941.0K $-240.0K $6M $3M · $201M
Financing Cash Flow 12-point trend, -117.1% $-48M $238M $188M $142M $23M $-148M $-2M $-2M $150M $987.0K $-2M $284M
Net Change in Cash 12-point trend, -103.3% $-3M $44M $-24M $-18M $-62M $90M $-44M $19M $15M $-156M $66M $100M
Free Cash Flow 11-point trend, +10.4% $-68M $-180M $-162M $-90M $-88M $-143M $114M $-149M $-186M $-176M · $-76M
Levered FCF 2-point trend, -134.0% · · · · · · · · · $-182M · $-78M
수익성 7
LXRX의 연간 수익성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Operating Margin 11-point trend, +77.6% -98.2% -634.2% -14264.9% -72489.2% -29224.8% -199.2% 43.9% -163.4% -151.3% -164.6% · -439.2%
Net Margin 11-point trend, +77.0% -101.1% -644.8% -14710.9% -73341.0% -29449.0% -244.1% 40.4% -190.7% -142.9% -169.7% · -438.8%
Pretax Margin 7-point trend, -6605.9% · · · · -29449.0% -244.1% 38.5% -190.7% -156.9% -169.7% · -439.1%
EBITDA Margin 11-point trend, +77.5% -97.0% -632.5% -14218.9% -72182.0% -29126.9% -187.0% 45.1% -157.6% -147.5% -162.1% · -430.7%
ROA 11-point trend, +22.6% -20.8% -75.9% -83.6% -61.6% -51.5% -18.9% 37.1% -33.5% -28.3% -25.1% · -26.9%
ROE 11-point trend, +10.1% -39.7% -167.7% -168.5% -88.4% -65.0% -42.8% 287.0% -576.0% -117.5% -63.8% · -44.2%
ROIC 2-point trend, -106.9% · · · · · · · · · -53.0% · -25.6%
유동성 및 지급능력 5
LXRX의 연간 유동성 및 지급능력 데이터
지표 추세 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, -40.5% 4.9 5.4 5.6 6.1 4.0 3.4 5.2 4.7 2.6 2.2 · 8.2
Quick Ratio 11-point trend, -37.6% 4.7 5.3 5.4 6.0 3.9 3.3 5.0 4.5 2.5 2.2 · 7.6
Debt / Equity 10-point trend, +32.5% 0.5 0.7 1.1 · 0.0 0.1 2.1 -9.3 4.7 0.6 · 0.4
LT Debt / Equity 9-point trend, +49.1% 0.5 0.7 1.1 · · 0.0 2.0 -9.2 4.4 0.5 · 0.3
Interest Coverage 8-point trend, +18.6% · · · -36.2 -108.6 -3.3 6.8 -5.0 -19.6 -20.9 · -44.5
효율성 3
LXRX의 연간 효율성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +236.1% 0.2 0.1 0.0 0.0 0.0 0.1 0.9 0.2 0.2 0.1 · 0.1
Inventory Turnover 7-point trend, -45.1% 1.1 2.0 0.4 · · 0.9 0.7 0.8 1.9 · · ·
Receivables Turnover 11-point trend, -32.1% 17.0 13.9 2.3 6.6 1.5 0.8 10.3 11.8 14.7 19.8 · 25.0
주당 5
LXRX의 연간 주당 데이터
지표 추세 202520242023202220212020201920182017201620152014
Book Value / Share 9-point trend, -24.9% $0.29 · · $0.62 $0.76 $1.10 $1.10 $-0.25 $0.49 $1.50 · $0.39
Revenue / Share 6-point trend, -95.0% $0.14 $0.10 $0.01 · $0.00 $0.22 $2.76 · · · · ·
Cash Flow / Share 6-point trend, -119.2% $-0.19 $-0.56 $-0.73 · $-0.60 $-1.29 $0.97 · · · · ·
Cash / Share 9-point trend, -50.4% $0.09 · · $0.24 $0.43 $0.89 $0.34 $0.76 $0.58 $0.45 · $0.19
EPS (TTM) 11-point trend, -16.7% $-0.14 $-0.63 $-0.80 $-0.62 $-0.60 $-0.53 $1.16 $-1.14 $-1.17 $-0.12 $-0.12 ·
성장률 3
LXRX의 연간 성장률 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, +161.0% 60.2% 2481.5% 766.2% -53.4% -98.8% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +1066.8% 610.2% 370.7% -63.1% · · · · · · · · ·
Revenue CAGR 5Y 15.7% · · · · · · · · · · ·
가치 평가 (TTM) 14
LXRX의 연간 가치 평가 (TTM) 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +117.9% $50M $31M $1M $139.0K $298.0K $24M $322M $63M $92M $79M $130M $23M
Net Income TTM 12-point trend, +49.8% $-50M $-200M $-177M $-102M $-88M $-59M $130M $-121M $-123M $-131M $-5M $-100M
Market Cap 9-point trend, -90.9% $421M · · $361M $591M $487M $443M $705M $1.04B $1.45B · $4.62B
Enterprise Value 8-point trend, -91.4% $378M · · · $505M $346M $416M $790M $979M $1.20B · $4.39B
P/E 11-point trend, +92.6% -8.2 -1.2 -1.9 -3.1 -6.6 -6.5 3.6 -5.8 -8.4 -115.2 -110.9 ·
P/S 9-point trend, -95.8% 8.4 · · 2600.0 1984.3 20.3 1.4 11.2 11.4 18.2 · 202.3
P/B 9-point trend, -76.0% 3.9 · · 3.1 5.2 3.1 3.8 -26.7 20.0 9.2 · 16.3
P / Tangible Book 4-point trend, +53.5% 6.7 · · 5.0 8.6 4.4 · · · · · ·
P / Cash Flow 9-point trend, +89.9% -6.2 · · -4.1 -6.8 -3.4 3.9 -4.7 -5.6 -8.2 · -61.1
P / FCF 9-point trend, +89.8% -6.2 · · -4.0 -6.7 -3.4 3.9 -4.7 -5.6 -8.2 · -61.1
EV / EBITDA 8-point trend, +82.4% -7.8 · · · -5.8 -7.7 2.9 -7.9 -7.3 -8.9 · -44.6
EV / FCF 8-point trend, +90.4% -5.6 · · · -5.7 -2.4 3.7 -5.3 -5.3 -6.8 · -58.0
EV / Revenue 8-point trend, -96.0% 7.6 · · · 1693.2 14.4 1.3 12.5 10.7 15.2 · 192.1
Earnings Yield 11-point trend, -1252.2% -12.2% -85.1% -52.3% -32.5% -15.2% -15.5% 28.0% -17.2% -11.8% -0.87% -0.90% ·

재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년

손익계산서
2025-12-312024-12-312023-12-312022-12-312021-12-31
매출 $50M$31M$1M$139.0K$298.0K
영업이익률 % -98.2%-634.2%-14264.9%-72489.2%-29224.8%
순이익 $-50M$-200M$-177M$-102M$-88M
희석 EPS $-0.14$-0.63$-0.80$-0.62$-0.60
대차대조표
2025-12-312024-12-312023-12-312022-12-312021-12-31
부채 / 자기자본 비율 0.50.71.1—0.0
유동비율 4.95.45.66.14.0
당좌 비율 4.75.35.46.03.9
현금 흐름
2025-12-312024-12-312023-12-312022-12-312021-12-31
잉여현금흐름 $-68M$-180M$-162M$-90M$-88M

최신 뉴스 이 회사 관련 최근 헤드라인

나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목

📊

중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.

선택 항목이 저장되어 모든 티커에서 유지됩니다.

기관 투자자 (13F) 169개의 제출자 · $760.9M 전체 · 기준일 2026년 6월 30일

분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.

기관 활동 — Q2 2026 대 이전 분기
신규 포지션 청산 포지션 증가함 감소 순주식 변동
48 (+19 이전 분기 대비) 26 (+13 이전 분기 대비) 34 (-11 이전 분기 대비) 37 (+17 이전 분기 대비) +36.5M

Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.

기관 가치 주식 % 추적된 13F 중 유형
Artal Group S.A. $420,374,549 175,156,062 55.25% 주식
Siren, L.L.C. $106,328,443 44,303,518 13.97% 주식
FMR LLC $65,057,059 27,107,108 8.55% 주식
Sessa Capital IM, L.P. $45,506,006 18,960,836 5.98% 주식
VANGUARD CAPITAL MANAGEMENT LLC $23,762,899 9,901,208 3.12% 주식
Point72 Asset Management, L.P. $19,803,180 8,251,325 2.60% 주식
GEODE CAPITAL MANAGEMENT, LLC $12,946,507 5,393,025 1.70% 주식
STATE STREET CORP $11,802,646 4,917,769 1.55% 주식
VANGUARD PORTFOLIO MANAGEMENT LLC $5,658,598 2,357,749 0.74% 주식
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $4,696,260 1,956,775 0.62% 주식
VANGUARD FIDUCIARY TRUST CO $3,922,970 1,634,571 0.52% 주식
CIBC Private Wealth Group LLC $3,240,347 2,400,257 0.43% 주식
Ishara Investments LP $3,050,400 1,271,000 0.40% 주식
MILLENNIUM MANAGEMENT LLC $2,722,150 1,134,229 0.36% 주식
RENAISSANCE TECHNOLOGIES LLC $2,704,800 1,127,000 0.36% 주식
MACKENZIE FINANCIAL CORP $2,312,050 963,354 0.30% 주식
ADAR1 Capital Management, LLC $1,800,000 750,000 0.24% 주식
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1,604,400 668,500 0.21% 콜 옵션
TWO SIGMA INVESTMENTS, LP $1,544,266 643,444 0.20% 주식
JANE STREET GROUP, LLC $1,398,960 582,900 0.18% 콜 옵션
CITADEL ADVISORS LLC $1,348,733 561,972 0.18% 주식
VANGUARD GROUP INC $1,277,587 1,110,945 0.17% 주식
Compagnie Lombard Odier SCmA $1,152,000 480,000 0.15% 주식
BARCLAYS PLC $890,636 371,098 0.12% 주식
CITADEL ADVISORS LLC $886,320 369,300 0.12% 콜 옵션
XTX Topco Ltd $858,905 357,877 0.11% 주식
GOLDMAN SACHS GROUP INC $725,810 302,421 0.10% 주식
CANADA PENSION PLAN INVESTMENT BOARD $618,960 257,900 0.08% 주식
RHUMBLINE ADVISERS $616,523 256,885 0.08% 주식
WELLS FARGO & COMPANY/MN $544,865 227,027 0.07% 주식
GROUP ONE TRADING LLC $420,031 175,013 0.06% 주식
Virtus Investment Advisers, LLC $408,996 170,415 0.05% 주식
Headlands Technologies LLC $401,275 167,198 0.05% 주식
Ikarian Capital, LLC $395,218 164,674 0.05% 주식
CITIGROUP INC $386,021 160,842 0.05% 주식
Quarry LP $374,846 156,186 0.05% 주식
MetLife Investment Management, LLC $351,384 146,410 0.05% 주식
Bank of New York Mellon Corp $345,307 143,878 0.05% 주식
BANK OF AMERICA CORP /DE/ $344,321 143,467 0.05% 주식
PANAGORA ASSET MANAGEMENT INC $316,901 132,042 0.04% 주식
State of Wyoming $285,816 119,090 0.04% 주식
BlackRock, Inc. $284,436 118,515 0.04% 주식
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $273,874 114,114 0.04% 주식
Cornerstone Investment Partners, LLC $272,974 113,739 0.04% 주식
Invesco Ltd. $238,190 99,246 0.03% 주식
ALGERT GLOBAL LLC $221,160 92,150 0.03% 주식
TWO SIGMA ADVISERS, LP $208,124 180,977 0.03% 주식
BANK OF NOVA SCOTIA $207,857 86,607 0.03% 주식
LPL Financial LLC $203,799 84,916 0.03% 주식
Vanguard Global Advisers, LLC $187,070 77,946 0.02% 주식
AQR CAPITAL MANAGEMENT LLC $180,101 75,042 0.02% 주식
Police & Firemen's Retirement System of New Jersey $176,165 73,402 0.02% 주식
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO $171,426 71,427 0.02% 주식
PRUDENTIAL FINANCIAL INC $171,228 71,345 0.02% 주식
MANUFACTURERS LIFE INSURANCE COMPANY, THE $167,393 69,747 0.02% 주식
NEW YORK STATE COMMON RETIREMENT FUND $164,160 68,400 0.02% 주식
TWO SIGMA SECURITIES, LLC $159,300 66,375 0.02% 주식
SEI INVESTMENTS CO $153,449 63,937 0.02% 주식
Nuveen, LLC $153,449 63,937 0.02% 주식
Straight Path Wealth Management $150,398 62,666 0.02% 주식
WELLINGTON MANAGEMENT GROUP LLP $144,000 60,000 0.02% 주식
R Squared Ltd $131,964 54,985 0.02% 주식
Vanguard Personalized Indexing Management, LLC $130,402 54,334 0.02% 주식
Fortis Group Advisors, LLC $120,000 50,000 0.02% 주식
Schonfeld Strategic Advisors LLC $118,642 49,435 0.02% 주식
SCOTIA CAPITAL INC. $117,291 48,871 0.02% 주식
PROFUND ADVISORS LLC $116,606 48,586 0.02% 주식
VOYA INVESTMENT MANAGEMENT LLC $114,650 47,771 0.02% 주식
AXQ CAPITAL, LP $109,745 45,727 0.01% 주식
BOOTHBAY FUND MANAGEMENT, LLC $106,356 44,315 0.01% 주식
ALLIANCEBERNSTEIN L.P. $105,768 67,800 0.01% 주식
WINTON GROUP Ltd $103,680 43,200 0.01% 주식
INTECH INVESTMENT MANAGEMENT LLC $101,978 42,491 0.01% 주식
LMR Partners LLP $98,618 41,091 0.01% 주식
BANK OF MONTREAL /CAN/ $96,000 40,000 0.01% 주식
NORTHERN TRUST CORP $93,794 39,081 0.01% 주식
BNP PARIBAS FINANCIAL MARKETS $90,672 37,780 0.01% 주식
Cubist Systematic Strategies, LLC $85,704 63,484 0.01% 주식
Rafferty Asset Management, LLC $81,816 34,090 0.01% 주식
ProShare Advisors LLC $78,212 32,588 0.01% 주식
Leonteq Securities AG $72,000 30,000 0.01% 주식
PINNACLE ASSOCIATES LTD $69,636 29,015 0.01% 주식
VICTORY CAPITAL MANAGEMENT INC $58,135 24,223 0.01% 주식
Legal & General Group Plc $58,044 24,185 0.01% 주식
XPONANCE LLC $57,031 23,763 0.01% 주식
Graham Capital Management, L.P. $56,498 23,541 0.01% 주식
D. E. Shaw & Co., Inc. $53,280 22,200 0.01% 주식
Quadrature Capital Ltd $52,795 21,998 0.01% 주식
Invera Wealth Advisors, LLC $48,000 20,000 0.01% 주식
DIKER MANAGEMENT LLC $48,000 20,000 0.01% 주식
TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC $48,000 20,000 0.01% 주식
Russell Investments Group, Ltd. $47,764 19,902 0.01% 주식
Point72 Asia (Singapore) Pte. Ltd. $47,282 35,024 0.01% 주식
Tower Research Capital LLC (TRC) $46,764 19,485 0.01% 주식
KWB Wealth $46,736 40,640 0.01% 주식
SBI Securities Co., Ltd. $46,092 19,205 0.01% 주식
PRINCIPAL FINANCIAL GROUP INC $45,682 19,034 0.01% 주식
CREDIT AGRICOLE S A $45,540 18,975 0.01% 주식
WOLVERINE TRADING, LLC $43,785 31,500 0.01% 풋 옵션
SUSQUEHANNA INTERNATIONAL GROUP, LLP $42,960 17,900 0.01% 풋 옵션

회사 내부자 49 명의 내부자 · 32 임원 · 19 이사

내부자 역할 마지막 활동 보유 주식 수 매수 12개월 매도 12개월 순매수/매도 12개월
Michael Exton Chief Executive Officer 2026년 2월 28일 M 298,432 0 0 $0
Lonnel Coats Chief Executive Officer 2024년 2월 28일 M 1,098,068 0 0 $0
Arthur T Sands President & CEO 2014년 2월 28일 M 1,021,329 0 0 $0
Scott M Coiante SVP, Chief Financial Officer 2026년 2월 28일 M 105,356 0 0 $0
Ajay Bansal EVP Corp Dev and CFO 2009년 6월 2일 A — 0 0 $0
Julia P Gregory EVP and CFO 2008년 2월 7일 A 50,200 0 0 $0
Jeffrey L Wade President and COO 2024년 7월 8일 A 324,214 0 0 $0
Rachel Yap Martens SVP, Partnerships & Corp Strat 2026년 2월 28일 M 31,264 0 0 $0
Suma Gopinathan SVP, Discovery 2026년 2월 28일 M 150,132 0 0 $0
Wendy Mcdermott SVP, Human Resources 2026년 2월 28일 M 277,945 0 0 $0
Craig B Granowitz SVP, Chief Medical Officer 2026년 2월 28일 M 323,430 0 0 $0
Lisa Defrancesco SVP, IR and Corp Comm 2026년 2월 28일 M 93,869 0 0 $0
Brian T Crum SVP, General Counsel & Secr. 2026년 2월 28일 M 428,802 0 0 $0
Kristen Alexander VP, Finance and Accounting 2025년 2월 28일 M 76,368 0 0 $0
Alan J Main EVP, Innov & Chem Sciences 2025년 2월 28일 M 339,104 0 0 $0
Brian Corrigan SVP, Regulatory & QA 2025년 2월 13일 A — 0 0 $0
Kenneth B. Kassler-Taub SVP, Regulatory & QA 2024년 2월 28일 M 162,672 0 0 $0
Thomas Garner SVP, Chief Commercial Officer 2024년 2월 8일 A — 0 0 $0
Kiernan Seth VP, Chief Commercial Officer 2023년 2월 28일 M 53,136 0 0 $0
James F Tessmer VP, Finance & Accounting 2021년 3월 15일 M 71,766 0 0 $0
Alexander A Santini EVP and CCO 2020년 4월 22일 F 55,584 0 0 $0
Pablo Lapuerta EVP and CMO 2020년 4월 22일 F 85,719 0 0 $0
John Northcott VP, Marketing, Comm Strategy 2015년 3월 2일 M 8,235 0 0 $0
Brian P Zambrowicz EVP, Chief Scientific Officer 2014년 2월 28일 M 278,703 0 0 $0
Steven Alan Tragash VP, Corporate Affairs 2010년 2월 15일 A — 0 0 $0
Philip M Brown SVP, Clinical Development 2010년 2월 15일 A 27,306 0 0 $0
James R Piggott PHD SVP of Pharm Bio 2008년 2월 7일 A 0 0 0 $0
Lance K Ishimoto SVP, Intellectual Property 2008년 2월 7일 A 10,200 0 0 $0
Tamar D Howson EVP of Bus Dev 2008년 2월 7일 A — 0 0 $0
Walter F Colbert SVP, HR and Corp Serv 2007년 2월 13일 A — 0 0 $0
Randall B Riggs SVP, Corp Licensing 2004년 2월 23일 M 15,000 0 0 $0
Christophe Person VP Informatics 2004년 1월 12일 M 0 0 0 $0
Ivan Cheung 이사 2026년 6월 3일 M 89,312 0 0 $0
Diane E. Sullivan 이사 2026년 6월 3일 M 126,122 0 0 $0
Judith L Swain 이사 2026년 6월 3일 M 174,486 0 0 $0
Amouyal Philippe 이사 2026년 6월 3일 M 374,486 0 0 $0
Sam L Barker 이사 2026년 6월 3일 M 213,771 0 0 $0
Christopher J Sobecki 이사 2026년 6월 3일 M 293,177 0 0 $0
Raymond Debbane 이사 2026년 6월 3일 M 1,995,498 7 0 $723,048
Robert J Lefkowitz MD 이사 2024년 5월 13일 A 48,364 0 0 $0
Frank Palantoni 이사 2023년 5월 21일 M 40,332 0 0 $0
Alan S Nies 이사 2023년 5월 21일 M 41,046 0 0 $0
Invus C.V. 이사 2020년 12월 31일 J 0 0 0 $0
Kathleen M Wiltsey 이사 2009년 4월 24일 A — 0 0 $0
Clayton Stuart Rose 이사 2007년 6월 26일 P 25,000 0 0 $0
Barry Mills 이사 2007년 4월 26일 A 25,000 0 0 $0
Patricia M Cloherty 이사 2006년 4월 27일 A — 0 0 $0
Thomas C Caskey 이사 2005년 10월 13일 P 6,300 0 0 $0
Praveen Tyle — 2021년 2월 28일 M 120,791 0 0 $0

SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당

행동주의자 및 5% 이상 소유자 11 보유

SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.

제출자 제출됨 지분 상태 목적 제출
Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 제출 서류 2026년 5월 8일 39.40% 수정본 — SEC
Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 제출 서류 2024년 12월 9일 — 최초 제출 — SEC
2012년 2월 24일 — 최초 제출 — SEC
Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) 2011년 12월 27일 — 최초 제출 — SEC
2011년 11월 14일 — 최초 제출 — SEC
2011년 8월 15일 — 최초 제출 — SEC
Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. 2010년 3월 19일 — 최초 제출 자본 구조 SEC
Estate of Gordon A. Cain (, Mary H. Cain ×4 제출 서류 2005년 8월 5일 — 최초 제출 — SEC
미공개 보고자, 미공개 보고자, 미공개 보고자 2003년 8월 8일 — 최초 제출 — SEC
미공개 보고자, 미공개 보고자, 미공개 보고자 2003년 7월 18일 — 최초 제출 수동적 투자 SEC
미공개 보고자, 미공개 보고자, 미공개 보고자, 미공개 보고자 2003년 3월 19일 — 최초 제출 — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF 보유 현황 14 ETF 보유

가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.

펀드 비중 단위 기준일 출처
QQQS · Invesco Exchange-Traded Fund Trust … 0.56% 51,356 SH 2026년 8월 8일 일간
IWC · iShares Trust 0.13% 841,693 SH 2026년 8월 8일 일간
VTWG · VANGUARD SCOTTSDALE FUNDS 0.04% 266,401 SH 2026년 8월 8일 일간
IWO · iShares Trust 0.04% 2,223,001 SH 2026년 8월 8일 일간
PRFZ · Invesco Exchange-Traded Fund Trust 0.03% 323,271 SH 2026년 8월 8일 일간
VTWO · VANGUARD SCOTTSDALE FUNDS 0.02% 1,432,882 SH 2026년 8월 8일 일간
IWM · iShares Trust 0.02% 6,194,737 SH 2026년 8월 8일 일간
VXF · VANGUARD INDEX FUNDS 0.01% 2,594,934 SH 2026년 8월 8일 일간
VHT · VANGUARD WORLD FUND 0.01% 637,561 SH 2026년 8월 8일 일간
SCHA · SCHWAB STRATEGIC TRUST 0.01% 1,032,223 NS 2026년 5월 31일 N-PORT
IWV · iShares Trust 0.00% 84,479 SH 2026년 8월 8일 일간
SCHB · SCHWAB STRATEGIC TRUST 0.00% 110,085 NS 2026년 5월 31일 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 7,083,651 SH 2026년 8월 8일 일간
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 20,905 SH 2026년 8월 8일 일간